Clinical trials: EGFR Activating Mutation
Non-small Cell Lung Cancer, Aquired Resistance
Acquired Resistant Mechanism of the First-generation EGFR TKIs
Patients with advanced non-small-cell lung cancer (NSCLC) harboring sensitive epithelial growth factor receptor (EGFR) mutations invariably develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs).
- Conditions
- Non-small Cell Lung Cancer, Aquired Resistance, EGFR TKIs
- Trial name
- NCT02804217
- Testing
- Genetic: mutation profile
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
This phase II trial studies how well targeted therapy works in treating patients with incurable non-small cell lung cancer with a genetic mutation.
- Conditions
- EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT02949843
- Testing
- Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Wake Forest University Health Sciences